UK +44 (0) 203 929 0534 | US +1 (917) 297-6587

Cross-Portfolio Strategy

How do we build a world-leading business in allogeneic cell therapy for solid tumours from scratch?

Our client, a world-leading biopharmaceutical company, was looking to make significant investments to establish a differentiated presence in cell and gene therapy. The ambitious strategy aimed to leap-frog current technologies with allogeneic approaches.

We partnered closely with senior business leadership, functional workstreams and their partner biotechs to develop an integrated cross-functional strategic playbook, extensively mapping the technology landscape and critical path.

To create the foundation for implementation, we developed a strategic build-up plan to establish a fully-fledged business unit including R&D, manufacturing and commercial. By helping think cross-functionally and long term, we were able drive critical dialogue on corporate strategy.

< Previous Case Study

Next Case Study >

Home                  Expertise                   Our Team                   Join us                    Contact us

Brand & Website design by GeoMedia           Privacy Policy

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Home                  Expertise                   Our Team                   Join Us                    Contact Us

Home                  Expertise                   Our Team
Join Us                    Contact Us

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Brand & Website design by GeoMedia          Privacy Policy